- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
ATL boosts power Doppler performance
ATL has released a new versionof its power mode color Doppler technology for imaging blood flowin small vessels. ATL increased the performance of the technologyand renamed it Color Power Angio Imaging, the Bothell, WA, companysaid last month. Color
ATL has released a new versionof its power mode color Doppler technology for imaging blood flowin small vessels. ATL increased the performance of the technologyand renamed it Color Power Angio Imaging, the Bothell, WA, companysaid last month.
Color Power Angio Imaging supersedes Doppler Power Imagingas the marketing term for the company's power mode Doppler technology.The technique displays the amplitude of blood flow rather thanthe velocity, giving physicians a better look at weak blood flowin small vessels.
Most major ultrasound vendors have adopted different versionsof Doppler blood-vessel roadmapping and the technology has beenwell received by clinicians. Few clinical papers on the technologyhave been published, due to its novelty, however. That could changewith this year's Radiological Society of North America meeting,according to ATL president David Perozek.
"At the RSNA conference there will be a number of clinicalpapers presented, indicating and evaluating the clinical utilityof the Color Power Angio mode," Perozek said.
Also last month, ATL released a new intraoperative scanheadfor vascular surgery applications. The Entos CL10-5 transducercan help vascular surgeons identify anatomic defects that mayresult from surgery, enabling them to take corrective action whilestill in the operating room, according to the company.
New Study Assesses Long-Term Outcomes of PSMA PET Use in PCa Recurrence Cases
October 24th 2024For patients with biochemical recurrence of prostate cancer, PSMA PET imaging may facilitate a 12.8 percent lower incidence of prostate cancer mortality in contrast to the combination of CT and bone scan, according to long-term outcome estimates from a new decision-analytic modeling study.
Can Diffusion MRI Predict Patient Response to Neoadjuvant Chemotherapy for Breast Cancer?
October 23rd 2024A model emphasizing time-dependent diffusion MRI was 15 percent more effective than apparent diffusion coefficient (ADC) measurements at predicting pathologic complete response to neoadjuvant chemotherapy for women with breast cancer, according to new research.
